Adaptive Biotechnologies Corporation Revenue 2017–2025
Adaptive Biotechnologies Corporation annual/quarterly revenue history and growth rate from 2017 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Adaptive Biotechnologies Corporation revenue for the quarter ending March 31, 2026 was 70.9 M, a 35.14% increase year-over-year.
- Adaptive Biotechnologies Corporation revenue for the twelve months ending March 31, 2026 was 276.2 M, a 63.01% increase year-over-year.
- Adaptive Biotechnologies Corporation annual revenue for 2025 was 277.0 M, a 54.77% increase from 2024.
- Adaptive Biotechnologies Corporation annual revenue for 2024 was 179.0 M, a 5.10% increase from 2023.
- Adaptive Biotechnologies Corporation annual revenue for 2023 was 170.3 M, a 8.11% decrease from 2022.
- Adaptive Biotechnologies Corporation annual revenue for 2022 was 185.3 M.
Adaptive Biotechnologies Corporation (ADPT) — Frequently Asked Questions
Adaptive Biotechnologies Corporation (ADPT) is a publicly traded US company. It has a market capitalization of $2.59B. In fiscal 2025 it reported revenue of $277M and net income of -$59M. Explore ADPT's stock price, financial statements, earnings history, margins and key ratios below.
What is Adaptive Biotechnologies Corporation's market cap?
Adaptive Biotechnologies Corporation (ADPT) has a market capitalization of $2.59B.
What is the ADPT stock price?
ADPT trades at $17.07 (-1.67% on the day).
How much revenue does Adaptive Biotechnologies Corporation make?
Adaptive Biotechnologies Corporation reported revenue of $277M in fiscal 2025.
Is ADPT profitable?
In fiscal 2025, Adaptive Biotechnologies Corporation reported net income of -$59M.